Research programme: PPAR dual gamma/delta agonists - Eli Lilly and Company
Latest Information Update: 16 Jul 2016
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 27 Sep 2006 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)